news
Grant to fund development of vaccines to prevent dementia
Researchers at Washington University are developing a vaccine using nanofiber technology to prevent dementia, offering a safer and more effective alternative to current treatments.
List view / Grid view
Alzheimer's disease (AD)
news
Engineers target neurons with modified lipid nanoparticles
Researchers at the University of Pennsylvania have engineered lipid nanoparticles to target neurons, advancing mRNA treatments for brain diseases.
article
How AI will reshape pharma in 2025
AI is set to transform drug development in 2025, streamlining processes and opening new possibilities. Learn how this technology is transforming clinical trials and reshaping the pharmaceutical industry.
news
Key enzyme discovery marks a step forward in Alzheimer’s treatment
Scientists have decoded the 3D structure of a key enzyme linked to Alzheimer's disease. This breakthrough opens up new possibilities for targeted drug development and better treatment options.
news
Blood-brain barrier breakthrough for ALS and Alzheimer’s disease
A new blood-brain barrier-crossing platform enables the delivery of therapeutic molecules to the brain, offering potential treatments for ALS and Alzheimer’s disease.
news
Carbonic anhydrase inhibitors protect against tau protein build-up
The glaucoma drug methazolamide removed tau build-up and lessened signs of dementia in genetically-engineered zebrafish and mice.
article
Organoids: the versatile platform for discovery and regeneration
Anirban Datta, Head of Discovery Biology at Verseon International Corporation, details how recent breakthroughs are bringing once-distant possibilities, such as testing drugs more efficiently and restoring lost organ function through implantation, closer to reality.
article
Alzheimer’s disease: driving advancements with precision medicine
In this Q&A, Simon Lovestone, Vice President, Global Head, Neuroscience Discovery and Translational Science at Johnson & Johnson, shares how they are leveraging the A/T/N biomarker framework to achieve breakthroughs in Alzheimer’s disease research, in an aim to alter disease progression before daily life is significantly affected.
news
Specific HERV expression signatures linked to MS and ALS
The study identified which specific HERVs are important in increasing susceptibility for neurodegenerative diseases.
news
New toxic component in the evolution of Alzheimer’s disease
UBneuro scientists discovered that reducing RTP801 expression prevented cognitive deficits and inflammation.
news
Mechanism that controls reactivation of neural stem cells discovered
New insights into the role of SUMOylation in the brain could lead to new targeted therapies for neurodegenerative conditions.
news
Promising development of new drug to treat Alzheimer’s disease
In lab and fruit fly studies, the new peptide inhibitor effectively acted on both major aggregation-promoting hotspots of Tau proteins.
news
New humanised neuroinflammation in vitro platform
Sygnature Discovery has created a platform named SCANME, which can scale up human disease modelling to develop novel therapeutics.
article
Drug candidates with blockbuster potential for CNS diseases
In this Q&A, Kristina Torfgård, CEO of IRLAB Therapeutics, discusses the Company’s current drug development pipeline, including two promising preclinical projects. Kristina also details their proprietary drug discovery and development platform which has enabled the production of many first-in-class candidates, and what she envisions for the future.
article
A novel class of drug candidates for neurodegenerative diseases
At AAIC 2024, AC Immune unveiled a new class of antibody drug conjugates, called morADC (Morphomer® antibody drug conjugate). In this Q&A, CEO of AC Immune, Andrea Pfeifer, discusses how morADC uses the capabilities of the company’s two discovery platforms to combine two highly selective molecules, resulting in drug candidates…